# Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.

> **NCT05379049** · — · UNKNOWN · sponsor: **University of Sulaimani** · enrollment: 80 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Inflammatory Arthritis
- Ankylosing Spondylitis

## Interventions

- **BIOLOGICAL:** Infliximab: Adalimumab; Etanercept;

## Key facts

- **NCT ID:** NCT05379049
- **Lead sponsor:** University of Sulaimani
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-10-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05379049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05379049, "Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05379049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*